

1 **Quercetin exerts anti-inflammatory effects via meanwhile suppressing *TLR2* gene**
2 **expression and STAT3 protein phosphorylation in activated inflammatory**
3 **macrophages**

4

5 Yi-Ru Liao and Jin-Yuarn Lin

6

7 Department of Food Science and Biotechnology, National Chung Hsing University,
8 Taichung City 402, Taiwan, R.O.C.

9

10 Correspondence to: Professor Jin-Yuarn Lin, Department of Food Science and
11 Biotechnology, National Chung Hsing University, 145 Xingda Rd., South Dist.,
12 Taichung City 402, Taiwan, R.O.C.

13 E-mail: jinlin@nchu.edu.tw

14

15

16 Running title: Anti-inflammatory signaling of Q in macrophages

1 ABSTRACT

2 Our previous studies demonstrated that quercetin (Q) could be ingested and
3 metabolized by macrophages and exerted prophylactic immuno-stimulatory activity
4 and therapeutic anti-inflammatory effects on lipopolysaccharide (LPS)-treated
5 macrophages *ex vivo*. To further clarify its possible anti-inflammatory mechanism, Q
6 was selected to treat mouse peritoneal macrophages that obtained from female BALB/c
7 mice exposed to LPS i.p. for 12 h. Relative gene expression of pro-/anti-inflammatory
8 (*TNF- α /IL-10*) cytokines and components of inflammation-related intracellular
9 signaling pathways (*TLR2*, *TLR4*, *NF- κ B*, *JAK2* and *STAT3*) was analyzed using two-
10 step reverse transcription (RT) and real-time quantitative polymerase chain reaction
11 (qPCR). STAT3 protein phosphorylation was determined using an in-cell ELISA
12 method. As a result, Q and its metabolite quercetin-3-O- β -D-glucuronide (Q3G)
13 decreased *TNF- α* gene expression amounts and ratios of pro-/anti-inflammatory (*TNF- α*
14 */IL-10*) cytokine gene expressions, but increased *IL-10* gene expression amounts in
15 activated inflammatory macrophages, supporting a substantial anti-inflammatory
16 potential of Q and Q3G treatments. However, Q3G had lower effects than those of Q.
17 Importantly, Q inhibited *TLR2* gene expression and phosphorylation of STAT3 protein
18 in the inflamed cells. Our results are the first report to suggest that Q inhibits LPS-
19 induced inflammation *ex vivo* through suppressing *TLR2* gene expression and STAT3
20 protein phosphorylation in activated inflammatory macrophages. Q has potential to
21 further apply for treating inflammation-associated diseases.

22

23 *Keywords:* activated inflammatory macrophages; quercetin; pro-/anti-inflammatory
24 cytokine genes; STAT3 protein phosphorylation; *TLR2*

1 **1. Introduction**

2

3 Quercetin (Q) is a potent bioflavonoid and widely found in foods. Q exhibits
4 extensive physiological and pharmacological benefits, including anti-inflammatory,
5 anti-proliferative, and anti-atherosclerotic effects in humans [1-3]. Among immune
6 cells, murine peritoneal macrophages are proven to ingest and metabolize Q *in vitro* [4].
7 After assimilation in macrophages, Q is metabolized to quercetin-3-O- β -D-glucuronide
8 (Q3G) that may further serve as an antioxidant metabolite in plasma [5,6]. Activated
9 inflammatory macrophages might be a potential target for Q metabolites within
10 injured/inflamed arteries [7]. Moreover, we found that treatments with Q inhibited
11 lipopolysaccharide (LPS)-induced inflammation in mouse peritoneal macrophages *ex*
12 *vivo* [8]. Most recently, oral supplementation with Q and galangin, alone or in
13 combination, are suggested to be promising therapeutic agents for atopic dermatitis
14 using a 2,4-dinitrochlorobenzene-induced mouse model [9].

15 Macrophages are innate cells throughout the body and function to trigger immune
16 responses and inflammation by mainly producing pro-inflammatory cytokine tumor
17 necrosis factor (TNF)- α and anti-inflammatory cytokine interleukin (IL)-10 [10,11].
18 Pro-/anti-inflammatory cytokine expression profiles by activated inflammatory cells,
19 particularly macrophages, may reflect inflammation status in the cells. Activated
20 inflammatory macrophages have been used to investigate anti-inflammatory effects of
21 active Q compounds [8,12,13].

22 Inflammation is a complicated biological response that can be triggered by extracellular
23 or/and intracellular factors such as lipopolysaccharides (LPS), pro-inflammatory
24 cytokines, and growth factors etc. [14]. Many adaptor proteins and transcription
25 factors in inflammatory cells continue inflammatory signal transductions [14]. One

1 of particular transcription factors, signal transducer and activator of transcription 3
2 (STAT3), is a member of the STAT protein family in response to LPS, cytokines, growth
3 factors etc. [14]. After stimulated by a ligand through its specific receptor (e.g. LPS
4 versus Toll like receptors (TLRs)), STAT3 located in cytoplasm is phosphorylated by
5 an adaptor protein, receptor-associated Janus kinases (JAK), and forms homo- or
6 heterodimers [14]. Activated STAT3 finally translocate to the compartment of the cell
7 nucleus where they serve as transcription activators and mediate a variety of gene
8 expressions in response to different cell stimuli [15]. Particularly, STAT3 is activated
9 until tyrosine 705 is phosphorylated in response to ligands such as interferons,
10 epidermal growth factor, IL-5, IL-6 etc. [14]. In contrast to tyrosine 705
11 phosphorylation, STAT3 may also be activated via serine 727 phosphorylation by
12 mitogen-activated protein kinases [16]. Undoubtedly, STAT3 plays an essential role
13 in cellular processes in response to inflammation, cell growth and apoptosis [15].
14 Targeted inhibition of JAK-STAT pathways, particularly STAT3, has been a potential
15 treatment strategy for obesity [17], atherosclerosis [18], prostate cancer, breast cancer
16 and hepatoma [19].
17 Recently, Q administration was found to reduce GP130, JAK1, and STAT3 activation
18 via IL-6 in glioblastoma cells, providing new insight into the role of Q as a blocker of
19 the STAT3 activation pathway stimulated by IL-6 [20]. The role of JAK-STAT
20 signaling in the anti-proliferative effects of dietary flavonoids in prostate cancer cells
21 has been found [21]. Q was found to actively accumulated in nuclear structures and
22 trigger specific gene expression in epithelial cells [22]. In addition, Q dose-
23 dependently inhibited TNF- α production and gene expression in peripheral blood
24 mononuclear cells by modulating *nuclear factor (NF)- κ B1* and *I κ B* [23]. Despite of
25 anti-inflammatory effects of Q have been demonstrated in both *in vitro* and *in vivo*

1 studies [8,24], its anti-inflammatory mechanism via intracellular signaling pathways in
2 activated inflammatory macrophages were not fully understood.

3 To unravel the possible anti-inflammatory mechanism of Q, activated inflammatory
4 macrophages isolated from the peritoneal cavity of mice injected intraperitoneally (i.p.)
5 with LPS for 12 h were treated with Q for 3 h *in vitro*. For comparison with the effect
6 of Q, Q3G, a major metabolite of Q, was also selected to perform. Changes in gene
7 expression amounts of pro-/anti-inflammatory cytokines, such as *TNF- α /IL-10*, and
8 components of inflammation-related intracellular signaling pathways, including *TLR2*,
9 *TLR4*, *NF- κ B*, *JAK2* and *STAT3*, in the activated inflammatory macrophages were
10 measured using two-step reverse transcription (RT) and real-time quantitative
11 polymerase chain reaction (qPCR). Phosphorylation of the STAT3 protein in the
12 activated inflammatory macrophages was determined using an in-cell enzyme-linked
13 immuno-sorbent assay (ELISA) method.

14

15 **2. Materials and methods**

16

17 *2.1. Sample preparation*

18

19 Quercetin (Q) (Sigma-Aldrich Co., Steinheim, Switzerland) and its metabolite
20 quercetin-3-O- β -D-glucuronide (Q3G) (Carbosynth Limited, Berkshire, UK) were
21 purchased at the highest available purity (>98%, HPLC) and prepared as described
22 previously [24].

23

24 *2.2. Experimental animals*

25

1 Female BALB/cByJNarl mice (7-week-old) were provided by the National Laboratory
2 Animal Center, National Applied Research Laboratories, Ministry of Science and
3 Technology in Taipei, Taiwan, ROC, and maintained in the Department of Food Science
4 and Biotechnology at National Chung Hsing University, Taiwan, ROC. The mice
5 were housed in an animal room with a 12-h-light and 12-h-dark cycle, constant
6 temperature (23 ± 2 °C) and relative humidity (50-75%). The experimental mice were
7 fed a laboratory standard diet (Diet MF 18, Oriental Yeast Co., Ltd., Osaka, Japan) and
8 free access to water ad libitum. After acclimatization for 1 week, the experimental
9 mice (8 weeks old) were randomly divided into two groups, including normal mice and
10 LPS-treated mice. The animal experiments used in the present study were reviewed
11 and approved by the Institutional Animal Care and Use Committee (IACUC), National
12 Chung Hsing University, Taiwan, ROC (IACUC Approval No: 98-101).

13

14 *2.3. Isolation of normal and activated inflammatory macrophages from experimental*
15 *mice*

16

17 A mild mouse systemic inflammation model using an intraperitoneal injection of LPS
18 at a concentration of 8 mg/kg body weight (BW) for 12 h was established in our
19 laboratory [8]. To isolate normal or activated inflammatory macrophages,
20 experimental mice (8 weeks old) were challenged with phosphate-buffered saline (PBS,
21 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na₂HPO₄, 1.5 mM KH₂PO₄, pH 7.4, 0.22 µm
22 filtered) or *Escherichia coli* LPS (O127:B8, Sigma-Aldrich Co., L-3129, St. Louis, MO)
23 at a dose of 8 mg/kg BW in a volume of 100 µl of LPS dissolved in sterilized PBS
24 using aliquots from a single lot of PBS or LPS. After PBS or LPS injection for 12 h,
25 the experimental mice sacrificed to isolate normal or activated inflammatory

1 macrophages, respectively [13,25]. The mice were anaesthetized with isoflurane (cat.
2 no., 4900-1605, Panion & BF Biotech Inc., Taipei, Taiwan) using a vaporizer (CAS-
3 01, Northern Vaporiser Limited, Cheshire, England, UK) and bled by retro-orbital
4 venous plexus puncture to collect blood. Then, the mice immediately sacrificed with
5 CO₂ to isolate primary peritoneal macrophages. Each mouse peritoneal cavity was
6 lavaged through peritoneum with 2 aliquots of 5 ml sterile Hank's balanced salts
7 solution (HBSS). The lavage fluid was collected and centrifuged at 4 °C, 400 ×g for
8 10 min to harvest cell pellets. The cell pellets that are peritoneal macrophages (>90%)
9 were collected and re-suspended in tissue culture medium (TCM, a serum replacement;
10 Celox Laboratories Inc., Lake Zurich, IL). The peritoneal macrophages isolated from
11 each animal were adjusted to a density of 2×10^6 cells/ml in TCM medium with a
12 hemocytometer using the trypan blue dye exclusion method for following experiments.

13

14 *2.4. Determination of an optimal incubation time for activated inflammatory* 15 *macrophages to express target cytokine genes*

16

17 To determine the optimal incubation time for expressing target cytokine genes in
18 activated inflammatory macrophages, isolated activated inflammatory macrophages (2
19 ml/well) were cultured with TCM medium (2 ml/well) in 6-well plates to achieve a final
20 cell density of 1×10^6 cells/ml. The plates were incubated at 37 °C in a humidified
21 incubator with 5% CO₂ and 95% air for 0, 3, 6, or 12 h, respectively. Throughout the
22 incubation, the plate was then centrifuged at 25°C, 400 × g for 10 min. The
23 supernatant was discarded and the cell pellet washed with 1 ml sterile PBS/well. The
24 cell pellet in the wells was collected to extract total RNA to analyze the gene expression
25 of pro-inflammatory cytokine (*TNF- α*) and anti-inflammatory cytokine (*IL-10*) using

1 RT and real-time qPCR assay. Changes in pro-/anti-inflammatory cytokine gene
2 expression profiles were selected as biomarkers for evaluating inflammation status in
3 the activated inflammatory macrophages. Based on the target cytokine gene
4 expression profiles, incubation of normal or activated inflammatory macrophages with
5 samples for 3 h *in vitro* was selected as an optimal incubation time for the following
6 studies.

7

8 *2.5. Effect of Q and Q3G on gene expression of target cytokines and components of* 9 *intracellular inflammation-related signaling pathway*

10

11 In our previous study, Q or Q3G treatments lower than 50 μM could not result in any
12 cytotoxicity on mouse peritoneal macrophages *in vitro* [24]. Therefore, Q or Q3G at
13 20 and 50 μM were selected to treat isolated normal or activated inflammatory
14 macrophages to re-verify anti-inflammatory potential and further determine a possible
15 anti-inflammatory mechanism. Isolated normal or activated inflammatory
16 macrophages (2 ml/well) were cultured with Q or Q3G (2 ml/well) at the indicated final
17 concentrations of 0, 20, and 50 μM in 6-well plates. Since glucocorticoid
18 dexamethasone (Dex) at 0.1 to 10 μM have been found to inhibit LPS-induced
19 inflammation in J774 macrophages *in vitro* [26], we chosen Dex at 1 μM as a positive
20 control for comparison. The plates were incubated at 37 °C in a humidified incubator
21 with 5% CO₂ and 95% air for 3 h, and then centrifuged at 25°C, 400 × g for 10 min.
22 The supernatant was discarded and the cell pellet washed with 4 ml sterile PBS. The
23 cell pellet in the wells was used to extract total RNA using TRIzol reagent (Invitrogen,
24 CA, USA). The isolated RNA samples from the treated cells were stored at -80°C for
25 future RT and real-time qPCR assay. Changes in the gene expression amounts of pro-

1 inflammatory cytokine (*TNF- α*) and anti-inflammatory cytokine (*IL-10*) were selected
2 as indicators for evaluating the anti-inflammatory potential of Q or Q3G. Changes in
3 the gene expression amounts of intracellular inflammation-related signaling
4 components, including *TLR2* and *STAT3*, were measured to determine possible anti-
5 inflammatory mechanisms of Q or Q3G.

6

7 2.6. Targeted gene expression assays

8

9 2.6.1. Extraction and quality evaluation of total RNA from treated cells

10 The extraction method was performed as described previously [27,28]. To evaluate
11 the quality of extracted total RNA, an aliquot of 2 μ l of RNA solution was pipetted into
12 a clean tube and then diluted 50 times with 10 mM Trizma hydrochloride (Tris-
13 HCl/DEPC, Sigma, MO, USA) buffer. Using a spectrophotometer (Hitachi-U2900
14 UV-vis spectrophotometer, Tokyo, Japan), both absorbance (A) at 260 and 280 nm of
15 each individual extracted RNA sample were measured. Based on the ratio of
16 A₂₆₀/A₂₈₀, values ranged from 1.5 to 2.0, indicating a high quality RNA and low
17 protein concentration in the extracted RNA sample. To load a fixed quantity for RNA
18 assay, the RNA concentration in the sample solution was roughly calculated using the
19 equation: 1 unit of A₂₆₀ = 40 μ g RNA/ml. At last, the extracted RNA samples were
20 stored at -80°C for subsequent two-step RT and real-time qPCR assay.

21

22 2.6.2. Synthesis of the first-strand cDNA using RT

23 An aliquot of 2 μ g of total RNA isolated from the treated cells was pipetted into a clean
24 tube. To prevent DNA contamination, DNA in the RNA sample was digested using a
25 commercial kit of RQ1 RNase-Free DNase (Promega, Madison, WI, USA). Then,

1 the first strand cDNA was produced from mRNA using a commercial kit of M-MLV
2 Reverse Transcriptase (Promega, Madison, WI, USA) which contains reaction buffer
3 (Promega, Madison, WI, USA), dNTP Mix 10 mM (Promega, Madison, WI, USA), and
4 Oligo dT (Invitrogen, CA, USA) in a total volume of 25 μ l. The reaction of reverse
5 transcription was performed for one cycle with the following program using a PCR
6 thermal cycler machine (Genesis 96; Pebio Scientific Company, Taipei, Taiwan): 25°C
7 for 5 min, 42°C for 60 min, 70 °C for 15 min, and followed by cooling to 4°C. After
8 the first cDNA was completely synthesized, the single strand cDNA sample was diluted
9 10-fold (v/v) in nuclease-free water and then stored at -80 °C for use.

10

11 2.6.3. Assay and data calculations of real-time qPCR

12 An aliquot of 5 μ l of diluted cDNA (cDNA template) was pipetted into a reaction tube,
13 which contained a mixture consisting of 4 μ l nuclease-free water, 10 μ l Smart Quant
14 Green Master Mix with dUTP low ROX (Protech, Taipei, Taiwan), 0.5 μ l target gene-
15 specific forward PCR primer (10 μ M), and 0.5 μ l target gene-specific reverse PCR
16 primer (10 μ M), to a final volume of 20 μ l. Primer sequences for detection of
17 expression of mouse cytokines and inflammation-related component genes using real-
18 time qPCR assays are shown in Table 1. Real-time qPCR reaction and detection were
19 performed in a real-time rotary analyzer (Rotor-Gene 6000; Corbett Life Science,
20 Sydney, Australia) using the following program: hot-start activation at 95 °C for 15 min,
21 followed by 40–50 cycles of denaturation at 95 °C for 30 s, annealing at 60 °C for 30
22 s, and extension at 72 °C for 30 s. The Ct (threshold cycle number) value of the target
23 gene expression was achieved according to fluorescence intensity measured using the
24 real-time rotary analyzer. Each biological determination was carried out in triplicate.
25 The comparative Ct method was used to quantify relative expression amounts of

1 targeted mRNA species, indicating that a lower Ct value corresponds to a higher mRNA
2 expression amount [21]. The stably expressed mouse β -actin, a housekeeping gene,
3 was selected as a reference for calibration. Relative gene expressions of pro-
4 inflammatory $TNF-\alpha$ and anti-inflammatory $IL-10$ cytokines, as well as components of
5 intracellular inflammation-related signaling, including $TLR2$ and $STAT3$ were measured.
6 Relative mRNA expression amounts in differently treated cells are expressed as the fold
7 change value. The expression ratio (R) of individual mRNA amount at treated vs.
8 control condition in the cells was determined using the equation: $R = 2^{-\Delta\Delta Ct}$ [29,30].
9 The following equations were used to calculate each target gene expression (e.g.,
10 cytokines or inflammation-related signaling) with respect to its control situation [31]:
11 $\Delta Ct = Ct_{\text{target gene}} - Ct_{\text{reference gene}}$ and $\Delta\Delta Ct = \Delta Ct_{\text{treatment}} - \Delta Ct_{\text{control}}$ or $\Delta\Delta Ct = (Ct_{\text{target gene}}$
12 $- Ct_{\beta\text{-actin gene}})_{\text{time x}} - (Ct_{\text{target gene}} - Ct_{\beta\text{-actin gene}})_{\text{time 0}}$.

13

14 2.7. Assay of $STAT3$ phosphorylation at tyrosine 705 using in-cell ELISA method

15

16 Phosphorylation of $STAT3$ is an active form of transcription factor $STAT3$ protein. After
17 phosphorylation in cytoplasm, phosphorylated $STAT3$ protein allows to move into the
18 cell nucleus for targeted gene transcription. To evaluate changes of activated $STAT3$
19 transcription factor amounts in target cells, $STAT3$ phosphorylation at tyrosine 705
20 were measured using an in-cell ELISA method. $STAT3$ phosphorylation in normal or
21 activated inflammatory macrophages treated without or with Q were further measured
22 to clarify the role of $STAT3$ phosphorylation at tyrosine 705 in inflammation. Briefly,
23 normal or activated inflammatory macrophages (50 μ l/well) were cultured in the
24 absence or presence of Q (50 μ l/well) at the indicated final concentrations of 0, 20, and
25 50 μ M in 96-well plates and incubated at 37 °C in a humidified incubator with 5% CO_2

1 and 95% air for 3 h. After incubation, the plate was centrifuged at 25 °C, 400 × g for
2 10 min to remove the supernatant. The cell pellet was collected to measure STAT3
3 phosphorylation at tyrosine 705 using a STAT3 Colorimetric In-Cell ELISA Kit (Pierce
4 Biotechnology, Rockford, IL, USA). Data were calculated with the average A450
5 value for each experimental condition (e.g., with and without treatment) for each target.
6 For assessing STAT protein modification with treatment, the fold change as a ratio of
7 A450 values from the treated and non-treated modified protein were calculated.

8

9 *2.8. Statistical analysis*

10

11 Values are expressed as means ± SEM and analyzed using one-way ANOVA, followed
12 by either Duncan's New Multiple Range test or unpaired Student's t-test. Differences
13 among treatments were considered statistically significant if $P < 0.05$. Statistical tests
14 were performed using SPSS version 12.0 (SPSS, Inc., Chicago, IL, USA).

15

16 **3. Results and discussion**

17

18 To unravel a possible anti-inflammatory mechanism of Q, normal and activated
19 inflammatory macrophages were isolated from mouse peritoneal cavities and cultured
20 with Q or its major metabolite Q3G *in vitro*. Changes of targeted cytokines gene
21 expression and components of inflammation-related intracellular signaling pathway in
22 the cells were determined using RT qPCR.

23

24 *3.1. Optimal incubation time for activated inflammatory macrophages in vitro for*
25 *mRNA expression assays*

1

2 To determine the optimal incubation time of mouse primary activated inflammatory
3 macrophages for mRNA expression assays, the target cytokine mRNA expression in
4 the cells was analyzed. The results showed that relative expression of target cytokines
5 in mouse primary activated inflammatory macrophages, including TNF- α and IL-10
6 changed in a time-dependent manner (Table 2). The relative expression level of TNF-
7 α was significantly different at all incubation times ($P < 0.05$). The expression of the
8 pro-inflammatory cytokine TNF- α was dominant at the early stage (e.g., incubation for
9 3 h), while that of the anti-inflammatory cytokine IL-10 was dominant at the late stage
10 (e.g., incubation for 12 h), which indicates inhibition of the synthesis of pro-
11 inflammatory cytokines during the inflammatory process. Thus, the highest fold
12 change in the ratio of pro-/anti-inflammatory cytokine gene expression (*TNF- α /IL-10*)
13 in mouse primary activated inflammatory macrophages was 6.89 ± 1.88 at 3 h-incubation.
14 Based on the most significance ($P < 0.05$) of cytokine gene expression profile (Table
15 2), the 3 h-incubation time was selected as optimal incubation time for the following
16 studies.

17

18 *3.2. Effect of Q or Q3G in vitro on the cytokine gene expression profile of activated*
19 *inflammatory macrophages*

20

21 To re-confirm the anti-inflammatory potential of Q based on pro- and anti-inflammatory
22 cytokine gene expression profile, the normal or activated inflammatory macrophages
23 were treated with Q or Q3G at the indicated non-toxic optimal concentrations (20 and
24 50 μ M) for 3 h [24]. The results showed that treatments of normal macrophages (from
25 mice treated i.p. with PBS for 12 h) with Q at 20 μ M significantly ($P < 0.05$) increased

1 mRNA expression amounts of both TNF- α and IL-10, but could not significantly ($P >$
2 0.05) change the ratio of pro-/anti-inflammatory (*TNF- α /IL-10*) cytokine gene
3 expressions (Table 3). Our results suggest that Q administration *in vitro* at the
4 indicated appropriate concentration of 20 μ M might activate primary normal
5 macrophages by increasing the mRNA expressions of both pro-inflammatory (TNF- α)
6 and anti-inflammatory (IL-10) cytokines, but overall slightly decreased inflammation
7 status by decreasing the ratio of pro-/anti-inflammatory (*TNF- α /IL-10*) cytokine gene
8 expression. Importantly, treatment of activated inflammatory macrophages (from
9 mice treated i.p. with LPS for 12 h) with Q at either 20 or 50 μ M significantly decreased
10 ($P < 0.05$) the mRNA expressions of TNF- α , but obviously increased those of IL-10
11 (Table 3). Q administration at either 20 or 50 μ M overall and significantly ($P < 0.05$)
12 inhibited the ratio of pro-/anti-inflammatory (*TNF- α /IL-10*) cytokine gene expressions
13 in activated inflammatory macrophages (Table 3). Our results evidence that Q exerts
14 substantive anti-inflammatory effects on activated inflammatory macrophages by
15 decreasing TNF- α mRNA expression amounts and ratios of pro-/anti-inflammatory
16 (*TNF- α /IL-10*) cytokine gene expressions, but increasing IL-10 mRNA expression
17 amounts. Interestingly, we found that Dex treatment effects on normal and activated
18 inflammatory macrophages *in vitro* were similar to those of Q, indicating that either
19 Dex or Q treatments had a therapeutic effect against inflammation. Corticosteroid-
20 like Dex is already used in clinical treatments for anti-inflammatory medications even
21 though it may cause adverse side effects. Q administration for inflammation treatment
22 may be an alternative choice to replace or reduce the clinical use of Dex in the future.
23 Pharmacokinetic areas under the plasma concentration-time curves of daily oral
24 supplementation with Q (50- and 150-mg dosages, respectively) ranged from 76.1
25 μ M \cdot min to 305.8 μ M \cdot min in volunteers with no apparent toxicity, suggesting Q

1 administration safety *in vivo* [32].

2 After Q is assimilated by macrophages, it may be further metabolized into Q3G. To
3 compare anti-inflammatory potential of Q and Q3G, Q3G were also selected to treat
4 normal and activated inflammatory macrophages for 3 h. The results showed that
5 Q3G administration to normal macrophages *in vitro* significantly increased *TNF- α* , but
6 just slightly increased *IL-10* gene expressions (Table 4). Moreover, Q3G significantly
7 ($P < 0.05$) increased the ratio of pro-/anti-inflammatory (*TNF- α /IL-10*) cytokine gene
8 expressions, suggesting that Q3G overall slightly increased inflammation status in
9 normal macrophages. Importantly, treatment of activated inflammatory macrophages
10 (from mice treated i.p. with LPS for 12 h) with Q3G at either 20 or 50 μ M significantly
11 decreased ($P < 0.05$) the mRNA expressions of *TNF- α* , but obviously increased those
12 of *IL-10* (Table 4). Q3G administration at either 20 or 50 μ M overall and significantly
13 ($P < 0.05$) inhibited the ratio of pro-/anti-inflammatory (*TNF- α /IL-10*) cytokine gene
14 expressions in activated inflammatory macrophages (Table 4). Our results evidence
15 that Q3G also exerts substantive anti-inflammatory effects on activated inflammatory
16 macrophages, but not normal macrophages, by decreasing *TNF- α* mRNA expression
17 amounts and ratios of pro-/anti-inflammatory (*TNF- α /IL-10*) cytokine gene expressions,
18 but increasing *IL-10* mRNA expression amounts.

19 Dex is a glucocorticoid that has been widely used to treat many inflammatory and
20 autoimmune diseases including rheumatoid arthritis, bronchospasm, and idiopathic
21 thrombocytopenic purpura [33]. In the present study, we show that Dex has
22 therapeutic (curative) effects in activated inflammatory diseases by regulating cytokine
23 secretion profiles in inflammatory cells. Similar to Dex administration effects, Q and
24 Q3G *in vitro* administrations overall decreased inflammation status in activated
25 inflammatory macrophages (Tables 3 and 4). Q has been found to have diverse

1 physiological effects, including antioxidant and anti-inflammatory effects in different
2 tissues [34,35]. Q3G is the major quercetin metabolite that is reported to have
3 antioxidant functions *in vitro*, and regulate coronary venous barrier function by
4 improving blood-borne inflammatory mediators in a novel microvascular wall model
5 [36]. In the present study, our results further suggest that Q and Q3G treatments *in*
6 *vitro* might have an immuno-stimulatory effect on normal macrophages, but inhibit
7 inflammation status in activated inflammatory macrophages by regulating cytokine
8 gene expressions (Tables 3 and 4). However, Q3G was found to have a lower anti-
9 inflammatory effect on normal macrophages than Q in this experimental model. We
10 hypothesize that the glycoside moiety in Q3G improves its water solubility, but
11 decreases its uptake by macrophages [37]. The uptake and metabolism of Q in mouse
12 primary macrophages have been previously described in our report [4]. Obviously, Q
13 has the better effect against inflammation than that of Q3G in both and normal and
14 activated inflammatory macrophages. To more accurately describe the anti-
15 inflammatory mechanism of Q, it was further applied to normal and activated
16 inflammatory macrophages for analyzing inflammation-related intracellular signaling
17 pathways.

18

19 *3.3. Effect of Q administration in vitro on relative gene expression amounts of*
20 *components of inflammation-related intracellular signaling pathway in normal or*
21 *activated inflammatory macrophages*

22

23 Table 5 shows the *in vitro* effects of Q on relative gene expression amounts of
24 components of inflammation-related intracellular signaling pathway, including *TLR2*,
25 *TLR4*, *NF-κB*, *JAK2*, and *STAT3*, in normal or activated inflammatory macrophages.

1 The results showed that Q administration more or less increased *TLR2*, *TLR4*, *NF-κB*,
2 *JAK2*, and *STAT3* gene expression amounts compared to those of controls in normal
3 macrophages (Table 5). In general, cultured primary macrophages that were isolated
4 from the body may result in slight spontaneous inflammation due to the change of
5 oxygen content in the environment. However, our results suggest that Q
6 administration at 50 μM might inhibit spontaneous inflammation in normal
7 macrophages via inhibiting the TLR2 signaling pathway. The physiological
8 significance of increased *NF-κB* and *STAT3* gene expression amounts induced by Q
9 might result from the immune-stimulatory property of Q and remains to be further
10 studied. In addition, we found that *TLR2* and *NF-κB* gene expression amounts
11 significantly ($P < 0.05$) increased, but *JAK2* and *STAT3* gene expression amounts
12 significantly decreased in activated inflammatory macrophages as compared to those
13 in normal macrophages (Table 5). Our results suggest that mice treated with LPS i.p.
14 may result in systemic inflammation and activate macrophage inflammation through
15 TLR2 to NF-κB intracellular signaling pathway in the activated inflammatory
16 macrophages. However, LPS treatment i.p. for 12 h may inhibit *JAK2* and *STAT3* gene
17 expressions in the activated inflammatory macrophages. Importantly, Q
18 administration *in vitro* significantly ($P < 0.05$) rectified the inflammation injury in the
19 activated inflammatory macrophages, via decreasing *TLR2* gene expression dose-
20 dependently, and improved inflammation damage to activated inflammatory
21 macrophages by increasing *JAK2* and *STAT3* gene expressions that were hindered in
22 the activated inflammatory macrophages (Table 5). The physiological significance of
23 increased *NF-κB* and *JAK2* gene expression in the activated inflammatory macrophages
24 by Q administration remains to be further investigated. It was found that purified
25 active lotus plumule (*Nelumbo nucifera* Gaertn) polysaccharides inhibited

1 inflammation in mouse primary splenocytes by decreasing *TLR2* and *TLR4* gene
2 expression [38]. Our results are identical to the published literature [38].
3 Similar to the administration effects of Q, Dex (positive control) at 1 μM *in vitro*
4 significantly improved the inflammation-induced injury in the activated inflammatory
5 macrophages ($P < 0.05$), by decreasing *TLR2* gene expression. However, *NF- κ B* and
6 *JAK2* gene expression in the activated inflammatory macrophages were significantly
7 ($P < 0.05$) increased by Dex administration (Table 5). Moreover, our results showed
8 that *STAT3* gene expression in both normal and activated inflammatory macrophages
9 were significantly increased by Q administration at appropriate concentrations *in vitro*
10 as compared to those of the controls ($P < 0.05$). Undoubtedly, *STAT3* gene expression
11 and activation influenced by Q plays an important role in inflammation. Thus, the
12 possible mechanism of *STAT3* activation through phosphorylation of *STAT3* protein at
13 tyrosine 705 was further measured in the present study.

14

15 *3.4. Effect of Q in vitro administration on phosphorylation of STAT3 at tyrosine 705 in*
16 *normal or activated inflammatory macrophages*

17

18 Phosphorylated *STAT3* protein is an active form of this transcription factor. To clarify
19 whether Q administration activated JAK-*STAT3* signaling through phosphorylation of
20 *STAT3* protein in normal or activated inflammatory macrophages, levels of *STAT3*
21 phosphorylation at tyrosine 705 were measured using an in-cell ELISA method.
22 Figure 1 shows Q *in vitro* administration effects on *STAT3* phosphorylation at tyrosine
23 705 in normal or activated inflammatory macrophages. The results showed that
24 *STAT3* protein phosphorylation at tyrosine 705 in activated inflammatory macrophages
25 significantly ($P < 0.05$) increased compared to that of normal control (Fig. 1), indicating

1 that LPS administration i.p. induced STAT3 phosphorylation in the activated
2 inflammatory macrophages. Most importantly, Q *in vitro* administration at 20 μ M
3 significantly ($P < 0.05$) inhibited STAT3 phosphorylation at tyrosine 705 in the
4 activated inflammatory macrophages, but did not significantly ($P > 0.05$) influence
5 normal macrophages. Our results suggest that Q administration might inhibit
6 inflammation status in the activated inflammatory macrophages by inhibiting the
7 signaling pathway involved in phosphorylation of STAT3 at tyrosine 705. However,
8 Dex treatment *in vitro* could not significantly ($P > 0.05$) change phosphorylation levels
9 of STAT3 protein at tyrosine 705 in both normal and activated inflammatory
10 macrophages ($P > 0.05$).

11 The present study indicates that Q administration inhibits the inflammation status in
12 activated inflammatory macrophages via regulation of cytokine gene expression. This
13 effect is mediated by decreased gene expressions of pro-inflammatory cytokine *TNF- α*
14 but increased anti-inflammatory cytokine *IL-10* (Table 3). In addition, Q
15 administration *in vitro* ameliorated the inflammation-induced injury in the activated
16 inflammatory macrophages by decreasing *TLR2* gene expression in a dose-dependent
17 manner and by increasing that of *JAK2* and *STAT3* genes, which had been suppressed
18 in the activated inflammatory macrophages (Table 5). Although *STAT3* gene
19 expression increased with Q administration, STAT3 phosphorylation at tyrosine 705 in
20 activated inflammatory macrophages (which was increased by LPS treatment i.p.) was
21 inhibited (Fig. 1). It was found that Q or its metabolites could enter macrophages to
22 exert their anti-inflammatory functions [5]. In the present study, we further
23 determined the effects of Q administration *in vitro* on components of inflammation-
24 related signaling pathway (TLR2 and TLR4) in activated inflammatory macrophages.
25 In addition, we infer that increased *NF- κ B* expression might inhibit *STAT3* expression

1 in the activated inflammatory macrophages in the absence of Q (Table 5). Both NF-
2 κ B and STAT3 are transcription factor in cells. Interestingly, Q administration seemed
3 to simultaneously increase both *NF- κ B* and *STAT3* gene expression in normal and
4 activated inflammatory macrophages (Table 5). The relationship between *STAT3* and
5 *NF- κ B* gene expression influenced by Q remains to be further clarified.

6 Some achievements have been obtained in the present study, and Q may be further
7 applied for anti-inflammatory clinical use including tumor therapy [9,14,18,39,40].
8 However, there are limitations in the present study. Firstly, this is still an *ex vivo* study;
9 therefore confirmation of the key findings *in vivo* using peritoneal challenge model
10 should be performed in the future. The findings with the murine cells may not be
11 recapitulated in the human cells. Unfortunately, changes of TLR and NF- κ B protein
12 levels in the cells were not determined so that the findings impact at the protein level
13 could not be confirmed. It remains unclear why Q increased the gene expression of
14 *STAT3*, but inhibited its phosphorylation. However, our results are the first report to
15 suggest that Q inhibits LPS-induced inflammation *ex vivo* through suppressing *TLR2*
16 gene expression and STAT3 phosphorylation in activated inflammatory macrophages.

17

18 **4. Conclusion**

19

20 This study evidenced that Q and its metabolite Q3G decreased *TNF- α* gene expression
21 amounts and ratios of pro-/anti-inflammatory (*TNF- α /IL-10*) cytokine gene expressions,
22 but increased *IL-10* gene expression amounts in activated inflammatory macrophages.
23 However, Q3G has similar, but lower, effects on activated inflammatory macrophages.
24 Importantly, Q inhibited *TLR2* gene expression and phosphorylation of STAT3 protein
25 in the inflamed macrophages. The present study supports that Q exerts anti-

1 inflammatory effects via meanwhile suppressing *TLR2* gene expression and STAT3
2 protein phosphorylation in activated inflammatory macrophages. Q has potential to
3 further apply for treating inflammation-associated diseases.

4

5 **Conflict of interest:** The authors declared no conflict of interest.

6

7 **Acknowledgment:** This study was kindly supported by research grant NSC99-2628-
8 B-005-004-MY3 from the Ministry of Science and Technology, Taipei, Taiwan, ROC.

1 References

- 2 [1] Y.J. Choi, X. Arzuaga, C.T. Kluemper, A. Caraballo, M. Toborek, B. Hennig,
3 Quercetin blocks caveolae-dependent pro-inflammatory responses induced by co-
4 planar PCBs. *Environ. Int.* 36 (2010) 931–934.
- 5 [2] R. Kleemann, L. Verschuren, M. Morrison, S. Zadelaar, M.J. van Erk, P.K.
6 Wielinga, T. Kooistra, Anti-inflammatory, anti-proliferative and anti-
7 atherosclerotic effects of quercetin in human *in vitro* and *in vivo* models.
8 *Atherosclerosis* 218 (2011) 44–52.
- 9 [3] D. Tang, R. Kang, W. Xiao, H. Zhang, M.T. Lotze, H. Wang, X. Xiao, Quercetin
10 prevents LPS-induced high-mobility group box 1 release and proinflammatory
11 function. *Am. J. Respir. Cell Mol. Biol.* 41 (2009) 651–660.
- 12 [4] C.J. Liu, Y.R. Liao, J.Y. Lin, Quercetin uptake and metabolism by murine
13 peritoneal macrophages *in vitro*. *J. Food Drug Anal.* 23 (2015) 692–700.
- 14 [5] C. Manach, O. Texier, F. Regeat, G. Agullo, C. Demigne, C. Remesy, Dietary
15 quercetin is recovered in rat plasma as conjugated derivatives of isorhamnetin and
16 quercetin. *J. Nutr. Biochem.* 7 (1996) 375–380.
- 17 [6] J.H. Moon, T. Tshida, K. Nakahara, J. Terao, Identification of quercetin 3-O- β -
18 D-glucuronide as an antioxidant metabolite in rat plasma after oral administration
19 of quercetin. *Free Radic. Biol. Med.* 30 (2001) 1274–1285.
- 20 [7] Y. Kawai, T. Nishikawa, Y. Shiba, S. Saito, K. Murota, N. Shibata, M. Kobayashi,
21 M. Kanayama, K. Uchida, J. Terao, Macrophage as a target of quercetin
22 glucuronides in human atherosclerotic arteries-Implication in the anti-
23 atherosclerotic mechanism of dietary flavonoids. *J. Biol. Chem.* 283 (2008) 9424–
24 9434.
- 25 [8] Y.R. Liao, J.Y. Lin, Quercetin intraperitoneal administration ameliorates

- 1 lipopolysaccharide-induced systemic inflammation in mice. *Life Sci.* 137 (2015)
2 89–97.
- 3 [9] H.N. Lee, S.A. Shin, G.S. Choo, H.J. Kim, Y.S. Park, B.S. Kim, S.K. Kim, S.D.
4 Cho, J.S. Nam, C.S. Choi, J.H. Che, B.K. Park, J.Y. Jung, Anti-inflammatory effect
5 of quercetin and galangin in LPS-stimulated RAW264.7 macrophages and DNCB-
6 induced atopic dermatitis animal models. *Int. J. Mol. Med.* 41 (2018) 888-898.
- 7 [10] S.J. Hopkins, The pathophysiological role of cytokines. *Leg. Med.* 5 (2003) S45–
8 57.
- 9 [11] J.Y. Lin, C.Y. Li, Proteinaceous constituents of red cabbage juice increase IL-10,
10 but decrease TNF- α secretions using LPS-stimulated mouse splenocytes. *J. Food*
11 *Drug Anal.* 18 (2010) 15–23.
- 12 [12] H.S. Kim, O.K. Kwon, J.W. Park, H.G. Jeong, S.R. Oh, H.K. Lee, T.T. Bach, D.V.
13 Hai, K.S. Ahn, Anti-inflammatory activities of methanol extract of *Mastixia*
14 *arborea* C.B. Clarke as to mouse macrophage and paw edema. *Biosci. Biotechnol.*
15 *Biochem.* 77 (2013) 2356–2361.
- 16 [13] C.J. Liu, J.Y. Lin, Anti-inflammatory and anti-apoptotic effects of strawberry and
17 mulberry fruit polysaccharides on lipopolysaccharide-stimulated macrophages
18 through modulating pro-/anti-inflammatory cytokines secretion and Bcl-2/Bak
19 protein ratio. *Food Chem. Toxicol.* 50 (2012) 3032–3039.
- 20 [14] L. Chen, H. Deng, H. Cui, J. Fang, Z. Zuo, J. Deng, Y. Li, X. Wang, L. Zhao,
21 Inflammatory responses and inflammation-associated diseases in organs.
22 *Oncotarget* 9 (2018) 7204-7218.
- 23 [15] Z.L. Yuan, Y.J. Guan, L. Wang, W. Wei, A.B. Kane, Y.E. Chin, Central role of the
24 threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3
25 constitutive phosphorylation in metastatic cancer cells. *Mol. Cell. Biol.* 24 (2004)

- 1 9390-9400.
- 2 [16] M. Tkach, C. Roseblit, M.A. Rivas, C.J. Proietti, M.C. Diaz Flaque, M.F.
3 Mercogliano, W. Beguelin, E. Maronna, P. Guzman, F.G. Gercovich, E.G. Deza,
4 P.V. Elizalde, R. Schillaci, MAPK-mediated StatSer272 phosphorylation is
5 required for progestin-induced full activation of Stat3 and breast cancer growth.
6 *Endocr.-Relat. Cancer* 20 (2013) 197-212.
- 7 [17] W. Hu, J. Lv, M. Han, Z. Yang, T. Li, S. Jiang, Y. Yang, STAT3: The art of multi-
8 tasking of metabolic and immune function in obesity. *Prog. Lipid Res.* 70 (2018)
9 17-28.
- 10 [18] Q. Chen, J. Lv, W. Yang, B. Xu, Z. Wang, Z. Yu, J. Wu, Y. Yang, Y. Han, Targeted
11 inhibition of STAT3 as a potential treatment strategy for atherosclerosis.
12 *Theranostics* 9 (2019) 6424-6442.
- 13 [19] E. Rubini, F. Altieri, S. Chichiarelli, F. Giamogante, S. Carissimi, G. Paglia, A.
14 Macone, M. Eufemi, STAT3, a hub protein of cellular signaling pathway, is
15 triggered by β -hexachlorocyclohexane. *Int. J. Mol. Sci.* 19 (2018) 2108.
16 doi:10.3390/ijms19072108.
- 17 [20] J. Michaud-Levesque, N. Bousquet-Gagnon, R. Béliveau, Quercetin abrogates IL-
18 6/STAT3 signaling and inhibits glioblastoma cell line growth and migration. *Exp.*
19 *Cell Res.* 318 (2012) 925–935.
- 20 [21] R. Aalinkeel, Z. Hu, B.B. Nair, D.E. Sykes, J.L. Reynolds, S.D. Mahajan, S.A.
21 Schwartz, Genomic analysis highlights the role of the JAK-STAT signaling in the
22 anti-proliferative effects of dietary flavonoids-‘Ashwagandha’ in prostate cancer
23 cells. *Evid.-based Complement. Altern. Med.* 7 (2010) 177–187.
- 24 [22] G. Notas, A.P. Nifli, M. Kampa, V. Pelekanou, V.I. Alexaki, P. Theodoropoulos, J.
25 Vercauteren, E. Castanas, Quercetin accumulates in nuclear structures and triggers

- 1 specific gene expression in epithelial cells. *J. Nutr. Biochem.* 23 (2012) 656–666.
- 2 [23] M.P. Nair, S. Mahajan, J.L. Reynolds, R. Aalinkeel, H. Nair, S.A. Schwartz, C.
3 Kandaswami, The flavonoid quercetin inhibits proinflammatory cytokine (tumor
4 necrosis factor alpha) gene expression in normal peripheral blood mononuclear
5 cells via modulation of the NF- κ B system. *Clin. Vaccine Immunol.* 13 (2006) 319–
6 328.
- 7 [24] Y.R. Liao, J.Y. Lin, Quercetin, but not its metabolite quercetin-3-glucuronide,
8 exerts prophylactic immuno-stimulatory activity and therapeutic anti-
9 inflammatory effect on lipopolysaccharide-treated mouse peritoneal macrophages
10 ex vivo. *J. Agric. Food Chem.* 62 (2014) 2872–2880.
- 11 [25] J.Y. Lin, C.Y. Tang, Strawberry, loquat, mulberry, and bitter melon juices exhibit
12 prophylactic effects on LPS-induced inflammation using murine peritoneal
13 macrophages. *Food Chem.* 107 (2008) 1587–1596.
- 14 [26] R. Korhonen, A. Lahti, M. Hamalainen, H. Kankaanranta, E. Moilanen,
15 Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide
16 production by destabilizing mRNA in lipopolysaccharide-treated macrophages.
17 *Mol. Pharmacol.* 62 (2002) 698–704.
- 18 [27] W.C. Lin, J.Y. Lin, Berberine down-regulates the Th1/Th2 cytokine gene
19 expression ratio in mouse primary splenocytes in the absence or presence of
20 lipopolysaccharide in a preventive manner. *Int. Immunopharmacol.* 11 (2011)
21 1984–1990.
- 22 [28] W.H. Chueh, J.Y. Lin JY, Protective effect of isoquinoline alkaloid berberine on
23 spontaneous inflammation in the spleen, liver and kidney of non-obese diabetic
24 mice through down-regulating gene expression ratios of pro-/anti-inflammatory or
25 Th1/Th2 cytokines. *Food Chem.* 131 (2012) 1263–1271.

- 1 [29] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-
2 time quantitative PCR and the $2(-\Delta\Delta C(T))$ method. *Methods* 25 (2001)
3 402–408.
- 4 [30] H.D. VanGuilder, K.E. Vrana, W.M. Freeman, Twenty-five years of quantitative
5 PCR for gene expression analysis. *Biotechniques* 44 (2008) 619–626.
- 6 [31] W.H. Chueh, J.Y. Lin, Berberine, an isoquinoline alkaloid, inhibits streptozotocin-
7 induced apoptosis in mouse pancreatic islets through down-regulating Bax/Bcl-2
8 gene expression ratio. *Food Chem.* 132 (2012) 252–260.
- 9 [32] S. Egert, S. Wolfram, A. Bosy-Westphal, C. Boesch-Saadatmandi, A.E. Wagner, J.
10 Frank, G. Rimbach, M.J. Mueller, Daily quercetin supplementation dose-
11 dependently increases plasma quercetin concentrations in healthy humans. *J. Nutr.*
12 138 (2008) 1615-1621.
- 13 [33] D. Provan, R. Stasi, A.C. Newland, V.S. Blanchette, P. Bolton-Maggs, J.B. Bussel,
14 B.H. Chong, D.B. Cines, T.B. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B.J.
15 Hunt, P.A. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M.A. Sanz, M.
16 Tarantino, S. Watson, J. Young, D.J. Kuter, International consensus report on the
17 investigation and management of primary immune thrombocytopenia. *Blood* 115
18 (2010) 168–186.
- 19 [34] A. Ishisaka, S. Ichikawa, H. Sakakibara, M.K. Piskula, T. Nakamura, Y. Kato, M.
20 Ito, K.I. Miyamoto, A. Tsuji, Y. Kawai, J. Terao, Accumulation of orally
21 administered quercetin in brain tissue and its antioxidative effects in rats. *Free*
22 *Radic. Biol. Med.* 51 (2011) 1329–1336.
- 23 [35] J.S. Yoon, M.K. Chae, S.Y. Lee, E.J. Lee, Anti-inflammatory effect of quercetin in
24 a whole orbital tissue culture of Graves' orbitopathy. *Br. J. Ophthalmol.* 96 (2012)
25 1117–1121.

- 1 [36] G. Juchem, D.R. Weiss, M. Knott, A. Senftl, S. Forch, T. Fischlein, E. Kreuzer, B.
2 Reichart, S. Laufer, S. Nees, Regulation of coronary venular barrier function by
3 blood borne inflammatory mediators and pharmacological tools: insights from
4 novel microvascular wall models. *Am. J. Physiol.-Heart Circul. Physiol.* 302 (2012)
5 H567–H581.
- 6 [37] W. Wiczkowski, J. Romaszko, A. Bucinski, D. Szawara-Nowak, J. Honke, H.
7 Zielinski, M.K. Piskula, Quercetin from shallots (*Allium cepa* L. var. *aggregatum*)
8 is more bioavailable than its glucosides. *J. Nutr.* 138 (2008) 885–888.
- 9 [38] C.H. Liao, J.Y. Lin, Purified active lotus plumule (*Nelumbo nucifera* Gaertn)
10 polysaccharides exert anti-inflammatory activity through decreasing Toll-like
11 receptor-2 and -4 expressions using mouse primary splenocytes. *J. Ethnopharmacol.*
12 147 (2013) 164–173.
- 13 [39] H.C. Lin, J.Y. Lin, Immune cell-conditioned media suppress prostate cancer PC-3
14 cell growth correlating with decreased proinflammatory/anti-inflammatory
15 cytokine ratios in the media using 5 selected crude polysaccharides. *Integr. Cancer*
16 *Ther.* 2016 (2016) 1-13.
- 17 [40] I. Jantan, W. Ahmad, S.N. Bukhari, Plant-derived immunomodulators: an insight
18 on their preclinical evaluation and clinical trials. *Front. Plant Sci.* 6 (2015) 655.
19 doi:10.3389/fpls.2015.00655.

Table 1

Primer sequences for detection of expressions of mouse cytokines and inflammation-related component genes using real-time qPCR assays.

Cytokine genes^a		Primer sequences^b	Length (bp)^c
<i>TNF-α</i>	FW	AGCCCCCAGTCTGTATCCTT	212
	RV	CTCCCTTGCAGAACTCAGG	
<i>IL-10</i>	FW	CATGGGTCTTGGGAAGAGAA	194
	RV	CATTCCCAGAGGAATTGCAT	
Inflammation-related component genes		Primer sequences	Length (bp)
<i>TLR2</i>	FW	TGCTTTCCTGCTGGAGATT	197
	RV	TGTAACGCAACAGCTTCAGG	
<i>TLR4</i>	FW	GGCAGCAGGTGGAATTGTAT	198
	RV	AGGCCCCAGAGTTTTTGTCT	
<i>NF-κB</i>	FW	TTCCTGGCGAGAGAAGCAC	202
	RV	AAGCTATGGATACTGCGGTCT	
<i>JAK2</i>	FW	GTCCACCCGTGGAATTTATG	198
	RV	GAAGGGAAAGGTCCCTGAAG	
<i>STAT3</i>	FW	GAGGAGCTGCAGCAGAAAGT	190
	RV	TCGTGGT AAA CTG GACACCA	
House-keeping gene		Primer sequences	Length (bp)
<i>β-actin</i>	FW	GCTACAGCTTCACCACCACA	208
	RV	AAGGAAGGCTGGAAAAGAGC	

^a IL, interleukin; TNF, tumor necrosis factor; TLR, toll-like receptor; ; NF- κ B, nuclear factor-kappaB; JAK2, Janus kinase 2; STAT3, signal transducers and activators of transcription 3. ^b FW, forward primer; RV, reverse primer. ^c Amplicon length in base pair.

Table 2

Effects of different incubation time with TCM medium *in vitro* on cytokine gene expressions in inflammatory macrophages from female BALB/c mice intraperitoneally injected with lipopolysaccharide at 8 mg/kg BW through 12 h.^{a, b}

Cytokines gene name	Incubation time (h)			
	0	3	6	12
Relative expression amount (fold)				
<i>TNF-α</i>	1.00 \pm 0.00 ^B	2.25 \pm 0.04 ^A	1.96 \pm 0.16 ^A	0.38 \pm 0.08 ^C
<i>IL-10</i>	1.00 \pm 0.00 ^{AB}	0.37 \pm 0.09 ^B	0.57 \pm 0.23 ^{AB}	1.22 \pm 0.32 ^A
<i>TNF-α/IL-10</i>	1.00 \pm 0.00 ^B	6.89 \pm 1.88 ^A	4.48 \pm 1.48 ^{AB}	0.69 \pm 0.23 ^B

^a Values are means \pm SEM (n = 3 biological determinations), analyzed using one-way ANOVA, followed by Duncan's new multiple range test. ^b Values within the same row not sharing a common superscript capital letter are significantly different ($P < 0.05$) from each other.

Table 3

Effects of quercetin administration on cytokine gene expression in activated peritoneal macrophages from female BALB/c mice intraperitoneally injected with phosphate-buffered saline or lipopolysaccharide at 8 mg/kg BW through 12 h.^{a, b, c}

Gene	Macrophages	Quercetin (μM)			Dex
		control	20	50	(1 μM)
Relative expression amount (fold)					
<i>TNF-α</i>	normal	1.00 \pm 0.00 ^B	23.2 \pm 7.5 ^A	9.69 \pm 1.06 ^B	2.95 \pm 0.39 ^B
	inflammatory	1.00 \pm 0.00 ^A	0.13 \pm 0.05 ^B	0.33 \pm 0.14 ^B	0.03 \pm 0.02 ^B
<i>IL-10</i>	normal	1.00 \pm 0.00 ^B	117 \pm 55 ^A	14.8 \pm 6.3 ^B	15.6 \pm 5.1 ^B
	inflammatory	1.00 \pm 0.00 ^B	12258 \pm 5518 ^A	9823 \pm 4212 ^{AB}	8271 \pm 2148 ^{AB}
<i>TNF-α/</i>	normal	1.00 \pm 0.00	0.71 \pm 0.54	0.96 \pm 0.51	0.16 \pm 0.09
<i>IL-10</i>	inflammatory	1.00 \pm 0.00 ^A	0.00 \pm 0.00 ^B	0.00 \pm 0.00 ^B	0.00 \pm 0.00 ^B

^a Values are means \pm SEM (n = 4 biological determinations), analyzed using one-way ANOVA, followed by Duncan's new multiple range test. ^b Values within same row not sharing a common superscript capital letter are significantly different ($P < 0.05$) from each other. ^c The collected peritoneal macrophages were cultured with quercetin or dexamethasone (Dex, a positive control) for 3 h *in vitro*.

Table 4

Effects of quercetin-3-glucuronide administration on cytokine gene expression in activated peritoneal macrophages from female BALB/c mice intraperitoneally injected with phosphate-buffered saline or lipopolysaccharide at 8 mg/kg BW through 12 h.^{a, b, c}

Gene	Macrophages	Quercetin-3-glucuronide (μM)			Dex
		0	20	50	(1 μM)
Relative expression amount (fold)					
<i>TNF-α</i>	normal	1.00 \pm 0.00 ^B	6.27 \pm 2.64 ^B	16.0 \pm 3.94 ^A	2.95 \pm 0.34 ^B
	inflammatory	1.00 \pm 0.00 ^A	0.08 \pm 0.03 ^B	0.14 \pm 0.05 ^B	0.03 \pm 0.01 ^B
<i>IL-10</i>	normal	1.00 \pm 0.00 ^B	5.33 \pm 2.87 ^B	7.10 \pm 1.46 ^B	15.6 \pm 4.5 ^A
	inflammatory	1.00 \pm 0.00 ^B	6155 \pm 2502 ^A	6813 \pm 1251 ^A	8271 \pm 1917 ^A
<i>TNF-α</i> / <i>IL-10</i>	normal	1.00 \pm 0.00 ^B	3.89 \pm 1.36 ^A	2.43 \pm 0.56 ^{AB}	0.25 \pm 0.07 ^B
	inflammatory	1.00 \pm 0.00 ^A	0.00 \pm 0.00 ^{BC}	0.00 \pm 0.00 ^B	0.00 \pm 0.00 ^C

^a Values are means \pm SEM (n = 5 biological determinations), analyzed using one-way ANOVA, followed by Duncan's new multiple range test. ^b Values within same row not sharing a common superscript capital letter are significantly different ($P < 0.05$) from each other. ^c The collected peritoneal macrophages were cultured with quercetin-3-glucuronide or dexamethasone (Dex, a positive control) for 3 h *in vitro*.

Table 5

Effects of quercetin administrations on relative gene expression folds of components in the inflammation-related signaling pathway in normal and inflammatory macrophages from female BALB/c mice intraperitoneally injected with phosphate-buffered saline or lipopolysaccharide at 8 mg/kg BW through 12 h.^{a, b, c, d}

Gene	Macrophages	Quercetin (μM)			Dex (1 μM)
		0	20	50	
Relative expression amount (fold)					
<i>TLR2</i>	normal	1.00 \pm 0.00 ^A	1.20 \pm 0.10 ^A	0.18 \pm 0.07 ^C	0.60 \pm 0.04 ^B
	inflammatory	2.76 \pm 0.31 ^{A,*}	0.83 \pm 0.15 ^B	0.49 \pm 0.24 ^B	0.18 \pm 0.06 ^B
<i>TLR4</i>	normal	1.00 \pm 0.00	11.8 \pm 8.29	14.1 \pm 12.1	1.42 \pm 0.16
	inflammatory	0.78 \pm 0.22 ^C	3.11 \pm 0.63 ^B	6.95 \pm 0.66 ^A	0.33 \pm 0.03 ^C
<i>NF-κB</i>	normal	1.00 \pm 0.00 ^{AB}	2.60 \pm 1.75 ^A	2.39 \pm 0.39 ^A	0.60 \pm 0.17 ^B
	inflammatory	2.19 \pm 1.20 ^{B,*}	3.90 \pm 1.65 ^{AB}	3.90 \pm 1.65 ^{AB}	6.68 \pm 2.83 ^A
<i>JAK2</i>	normal	1.00 \pm 0.00	1.61 \pm 0.71	1.60 \pm 0.84	0.54 \pm 0.22
	inflammatory	0.54 \pm 0.11 ^{B,*}	1.01 \pm 0.23 ^{AB}	1.74 \pm 0.33 ^A	1.74 \pm 0.35 ^A
<i>STAT3</i>	normal	1.00 \pm 0.00 ^B	6.00 \pm 1.50 ^A	1.81 \pm 0.86 ^B	0.67 \pm 0.17 ^B
	inflammatory	0.59 \pm 0.17 ^{B,*}	1.17 \pm 0.21 ^A	1.14 \pm 0.19 ^A	0.40 \pm 0.12 ^B

^a Values are means \pm SEM (n = 4 biological determinations), analyzed using one-way ANOVA, followed by Duncan's new multiple range test. ^b Values within same row not sharing a common superscript capital letter are significantly different ($P < 0.05$) from each other. ^c Asterisk (*) within same gene item means significantly different ($P < 0.05$) between normal and inflammatory macrophages in the absence of quercetin, analyzed using one-way ANOVA, followed by unpaired Student's *t*-test. ^d The peritoneal macrophages were cultured with quercetin or dexamethasone (Dex, a positive control) for 3 h *in vitro*.

Figure legends

Fig. 1. Effect of quercetin administration on phospho-STAT3 (Tyr705) protein levels in normal and inflammatory macrophages from female BALB/c mice.

^a Values are mean \pm SEM (n = 5 biological determinations) analyzed using one-way ANOVA, followed by Duncan's new multiple range test. ^b Bar under the same condition not sharing a common letter are significantly different ($P < 0.05$) from each other. ^c Asterisk (*) means significantly different ($P < 0.05$) between normal and inflammatory cells in the absence of sample, analyzed using unpaired Student's *t*-test.

^d The peritoneal macrophages were cultured with quercetin or dexamethasone (Dex, a positive control) for 3 h *in vitro*.

Fig. 1

